Evidence map›Paper›PMID 41343120›Full record

ArticlePulmonary therapy2026

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center.

Marco Cipolli, Teja Thorat, Pia C Pafundi, Alessandro Roggeri, Daniela P Roggeri, Carlotta Rossi, Emily Pintani, Ilaria Meneghelli, Francesca Lucca, Anna Fratoni and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marco CipolliCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale A. Stefani, 1-37126, Verona, Italy. Marco.cipolli@aovr.veneto.it.ORCID http://orcid.org/0000-0001-5652-7248
Teja ThoratVertex Pharmaceuticals Incorporated, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2856-752X
Pia C PafundiVertex Pharmaceuticals Incorporated, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0310-3529
Alessandro RoggeriProCure Solutions Nembro, Nembro, BG, Italy.ORCID http://orcid.org/0000-0002-9664-0306
Daniela P RoggeriProCure Solutions Nembro, Nembro, BG, Italy.ORCID http://orcid.org/0000-0003-4676-4164
Carlotta RossiProCure Solutions Nembro, Nembro, BG, Italy.ORCID http://orcid.org/0000-0001-9133-971X
Emily PintaniCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale A. Stefani, 1-37126, Verona, Italy.
Ilaria MeneghelliCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale A. Stefani, 1-37126, Verona, Italy.
Francesca LuccaCystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale A. Stefani, 1-37126, Verona, Italy.ORCID http://orcid.org/0000-0002-5294-9301
Anna FratoniVertex Pharmaceuticals Incorporated, Boston, MA, USA.
Gabriela Vega-HernandezVertex Pharmaceuticals Incorporated, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn Italy, elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in combination with ivacaftor was reimbursed starting July 2021 for use in people with cystic fibrosis (CF) aged ≥ 12 years homozygous for F508del mutation or heterozygous with at least one F508del allele and with a minimal function mutation. This study assessed the impact of ELX/TEZ/IVA on real-world outcomes among this population in Italy.

methodsThis observational study used data from Verona CF Center from October 2018 to December 2022 to describe the impact of ELX/TEZ/IVA on individuals aged ≥ 12 years with ≥ 1 F508del allele on lung function and healthcare resource utilization (HCRU). Lung function (percent predicted forced expiratory volume in 1 s [ppFEV

resultsA total of 149 individuals were included (mean [standard deviation, SD] age: 32.6 [12.25] years). A mean improvement in ppFEV

conclusionSubstantial improvements in lung function and reductions in HCRU were observed after treatment with ELX/TEZ/IVA in the Verona CF Center. Results contribute to the growing evidence of country-specific real-world data on the positive impact of ELX/TEZ/IVA.

Indexed as

Cystic fibrosisElexacaftor/tezacaftor/ivacaftorHealthcare resource utilizationReal-world evidence

Identifiers

PMID41343120
PMCPMC12992851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.